CD274 and posterior uveitis: Atezolizumab (anti-PD-L1) had a heavy tendency towards posterior uveitis, with a percentage of posterior uveitis cases three-fold higher than any other ICIs (80% vs. 23.7%), while no cases of anterior uveitis were reported.